Josep Samitier Archives - Page 8 of 10 - Institute for Bioengineering of Catalonia

Imaginenano Online 2020

Imaginenano2020 Online Imaginenano2020 organisers have been closely monitoring global developments of the COVID-19 virus since the start of the year. The health and safety of our speakers, exhibitors, participants and … Read more

Josep Samitier talks about the reallocation of the research funds

Josep Samitier, director of IBEC and president of ACER, the association of Catalan research centers, talks in an interview at the “Ara” newspaper about the reallocation of funds.

New method could help to find the best treatment for a pediatric cancer

A study led by IBEC researchers from the Nanobioengineering group, uses a functional predictive biomarker to anticipate the effect of treatments against rhabdomyosarcoma, the most common soft-tissue cancer affecting childhood and adolescence.

This advance can help in predicting treatment efficiency thus, avoiding tumor resistance and decreasing undesired secondary effects.

Nanoscale cellular adhesion is a key factor for cartilage production in vitro

Researchers from the Institute of Bioengineering of Catalonia (IBEC) develop a methodology based on nanopatterned structures which improves the differentiation of mesenchymal stem cells into cartilage in vitro. This advance might be applied to cartilage regeneration techniques aiming to treat lesions.

Josep Samitier, awarded with the Narcís Monturiol medal for his contribution to science and technology

The Catalan Government announced yesterday the Narcís Monturiol Medal award for scientific and technological merit to the Director of the IBEC, Josep Samitier Martí, for his contribution to the development of the Catalan system of science and technology.

In total, ten researchers from the Catalan knowledge system (six men and four women) have received this distinction, as well as a research center that has been awarded the Narcís Monturiol Plaque, which recognizes an institution in the country.

Bioengineering against the most resistant and deadly bacterial infections

An international team, led by Profs Giuseppe Battaglia and Loris Rizzello from the Institute for Bioengineering of Catalonia (IBEC), carried out out a study that opens the door to a new therapy capable of quickly and effectively eliminating infections caused by intracellular bacteria, the most resistant to immune defenses.

This therapy, based on synthetic vesicles, could considerably reduce the dose and duration of antimicrobial treatments, thus reducing the danger of generating resistance to antibiotics of pathogens such as those leading to tuberculosis.

Josep Samitier talks about how the redistribution of funds will affect research

Josep Samitier, director of the Institute for Bioengineering of Catalonia and president of the Catalan Association of Research Entities (ACER), assesses how science and technology can be affected by the fact that 53 million euros, that had to be invested in research, have been redirected to the healthcare sector, due to the coronavirus outbreak.

IBEC receives a visit from the Mayor of Barcelona interested in our research against Covid19

The Mayor of Barcelona, Ada Colau, visited IBEC facilities last Friday to learn, by our Director and a group of researchers, how bioengineering can help find solutions to health problems such as COVID19, cancer, or degenerative diseases.

When in early 2020, more than 200 scientists gathered in La Pedrera in Barcelona to discuss the present and future of bioengineering, no one imagined that the world would experience the first pandemic of the 21st century and that science would take on more importance than ever.

IBEC’s director contributes to the new National Agreement for a Knowledge-based Society

On May 13, the new National Agreement for a Knowledge-based Society was presented at the appearance of the President of the Catalan Government and the Minister for Business and Knowledge.

This pact proposes the public policies that would have to be carried out so that Catalonia to becomes a leader in research and innovation at the international level.

Bioengineering contributes to new advances against childhood cancer

IBEC contributes to elucidate how the rigidity of the tumor extracellular matrix affects the aggressiveness of neuroblastoma, a cancerous tumor that affects mainly children. This opens the door to generate more accurate models to predict tumor development in patients and to work in the design of new treatments.

Neuroblastoma is the most frequent malignant tumor in the first year of life. It is caused by a genetic mutation from immature nerve cells (neuroblasts) that the fetus produces as part of its development process.